aTyr Pharma, Inc. - Asset Resilience Ratio
aTyr Pharma, Inc. (ATYR) has an Asset Resilience Ratio of 72.16% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ATYR current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how aTyr Pharma, Inc.'s Asset Resilience Ratio has changed over time. See ATYR total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down aTyr Pharma, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see aTyr Pharma, Inc. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.94 Million | 72.16% |
| Total Liquid Assets | $67.94 Million | 72.16% |
Asset Resilience Insights
- Very High Liquidity: aTyr Pharma, Inc. maintains exceptional liquid asset reserves at 72.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
aTyr Pharma, Inc. Industry Peers by Asset Resilience Ratio
Compare aTyr Pharma, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for aTyr Pharma, Inc. (2014–2025)
The table below shows the annual Asset Resilience Ratio data for aTyr Pharma, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 72.16% | $67.94 Million | $94.16 Million | +9.09pp |
| 2024-12-31 | 63.07% | $61.07 Million | $96.83 Million | +0.39pp |
| 2023-12-31 | 62.68% | $75.62 Million | $120.65 Million | +4.04pp |
| 2022-12-31 | 58.64% | $56.16 Million | $95.79 Million | -32.74pp |
| 2021-12-31 | 91.38% | $105.58 Million | $115.54 Million | +53.32pp |
| 2020-12-31 | 38.05% | $14.74 Million | $38.73 Million | -22.56pp |
| 2019-12-31 | 60.61% | $21.93 Million | $36.19 Million | +10.21pp |
| 2018-12-31 | 50.40% | $26.58 Million | $52.75 Million | -21.26pp |
| 2017-12-31 | 71.66% | $64.03 Million | $89.36 Million | +29.73pp |
| 2016-12-31 | 41.92% | $33.76 Million | $80.52 Million | +9.14pp |
| 2015-12-31 | 32.78% | $42.51 Million | $129.68 Million | +23.32pp |
| 2014-12-31 | 9.47% | $1.95 Million | $20.64 Million | -- |
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinica… Read more